Tirzepatide Linked to Lower Risk of Cardiovascular Events
Tirzepatide cuts major cardiovascular risks by 32% compared to sitagliptin in adults with type 2 diabetes and cardiovascular disease, according to a recent population-based cohort study. While providing vital heart ... Read More